Oxaliplatin Bendalis

Oxaliplatin, the active ingredient in Oxaliplatin Bendalis, is a platinum‑based antineoplastic agent presented as a sterile powder for intravenous infusion use. It is employed in combination chemotherapy regimens for the treatment of certain solid tumours, most commonly colorectal cancer, in adult patients.

GNH USA supplies Oxaliplatin Bendalis as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Oxaliplatin Bendalis is a platinum‑based chemotherapy drug that acts on malignant cells in the gastrointestinal and other solid‑tumour pathways. - Colorectal cancer: used in adjuvant or metastatic settings to inhibit tumour growth. - Gastric cancer: combined with other agents to improve response rates. - Pancreatic cancer: part of multi‑drug regimens aiming to prolong survival. - Ovarian cancer: incorporated in certain protocols for platinum‑sensitive disease. - Small‑cell lung cancer: used off‑label in some European centres as part of salvage therapy.

Oxaliplatin Bendalis may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Peripheral neuropathy: tingling or numbness, often dose‑related. - Diarrhoea: watery stools that may require supportive care. - Fatigue: generalized tiredness during treatment cycles. - Thrombocytopenia: reduced platelet count increasing bleed risk.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Acute pulmonary toxicity: shortness of breath or infiltrates on imaging. - Hemolytic‑uremic syndrome: rare renal and hematologic complication. - Persistent neurotoxicity: long‑lasting sensory deficits. - Cardiotoxicity: arrhythmias or myocardial injury in susceptible patients.

When handling Oxaliplatin Bendalis, clinicians should observe several safety measures to protect patients and staff. - Renal function monitoring: assess creatinine clearance before each cycle. - Hepatic function monitoring: check liver enzymes regularly. - Neuropathy assessment: evaluate sensory changes before and during therapy. - Hematologic monitoring: complete blood count to detect cytopenias. - Pregnancy and lactation: avoid use; discuss contraception with women of childbearing potential. - Store at below 25°C: keep in original container, protect from light and moisture.

Oxaliplatin Bendalis can interact with other medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - Concurrent use of other platinum agents: additive nephrotoxicity and neurotoxicity. - High‑dose vitamin C infusions: may reduce platinum‑DNA binding and diminish anticancer effect.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): increased bleeding risk due to thrombocytopenia. - CYP‑modulating drugs: may affect supportive‑care agents metabolised by CYP enzymes. - NSAIDs and aspirin: heightened risk of gastrointestinal irritation when combined with anti‑emetics. - Radiotherapy to the abdomen: potential for enhanced mucosal toxicity. - Immunosuppressants: monitor for infection due to combined myelosuppression.